Pfizer and biontech receive positive chmp opinion for omicron jn.1-adapted covid-19 vaccine in the european union

New york and mainz, germany, june 27, 2024 — pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended marketing authorization for the companies' omicron jn.1-adapted monovalent covid-19 vaccine (comirnaty® jn.1) for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. the adaptation is based on the recommendation from the world health organization (who) technical advisory group on covid-19 vaccine composition and the european medicines agency's emergency task force (etf) to update covid-19 vaccines to target the sars-cov-2 variant jn.1 for the 2024-2025 vaccination campaign. etf stated that “evidence indicates that targeting jn.1 will help maintain the effectiveness of the vaccines as sars-cov-2 continues to evolve.” 1, 2
BNTX Ratings Summary
BNTX Quant Ranking